Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, October 24, 2013 at 9 a.m. ET to discuss third quarter 2013 financial and operational results. The webcast can be accessed from the Investor Relations page of the Company’s Web site at www.celgene.com. Celgene will also host a webcast of an investor event at the American College of Rheumatology (ACR) Meeting on Sunday, October 27 at 6:30 p.m. PT (9:30 p.m. ET). Members of Celgene’s management team and clinical investigators will discuss the data presentations at the ACR Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company’s web site at www.celgene.com. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com. Forward-Looking Statements This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.